Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis
Abstract Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach. Methods A systematic literature search was conducted in the Medline, Embase, and Web of Science databases. El...
Saved in:
| Main Authors: | Chaoyang Wang, Dong Xiao, Chao Zhai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14404-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis
by: John Crown, et al.
Published: (2025-06-01) -
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01) -
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
by: Yu Zhang, et al.
Published: (2025-07-01) -
Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database
by: Jinming Han, et al.
Published: (2025-04-01) -
Efficacy and safety of TACE combined with TKIs and PD-1 inhibitors in HCC patients with prior TIPS
by: Kai Xiong, et al.
Published: (2025-04-01)